59 results about "Pyranose" patented technology

The present invention relates to a D-galactopyranose compound of formula (1)whereinthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and / or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

Provided are methods for producing polysaccharides in bacteria by expressing in a bacterium one or more coding sequences selected from the group consisting of a pglF dehydrogenase coding sequence, a wbpP UDP-N-acetyl-d-glucosamine C4 epimerase coding sequence, a wcfR aminotransferase coding sequence, and a wcfS phospho-glycosyltransferase coding sequence, a wcfQ glycosyltransferase coding sequence, a wcfO pyruvyltransferase coding sequence, a wcfP glycosyltransferase coding sequence, a wcfM UDP-galactopyranose mutase coding sequence, a wcfN glycosyltransferase coding sequence, a wza polysaccharide export protein coding sequence, a wzx fippase coding sequence, a wzy polymerase coding sequence, and a wzz coding sequence, wherein at least one of the coding sequences is heterologous to the bacterium. Also provided are expression cassettes with one or more of the disclosed coding sequences, recombinant bacteria that harbor one or more of the expression cassettes, and methods for producing immunogenic compositions using the polysaccharides produced by the recombinant bacteria.

The present invention relates to a crystalline form of a glucopyranosyl derivative and its use. In particular, the present invention relates to a crystalline form of N-(2-dimethylaminoethyl)-1-[4-[4-[[5-[(2S,3R,4S,5S,6R)-6-ethyl-3,4,5-trihydroxy-tetrahydropyran-2-yl]-2-methyl-phenyl]methyl]phenyl]butyrylamino]cyclohexylformamide and a pharmaceutical composition comprising the crystalline form, and further to the use of the crystalline form and the pharmaceutical composition in the preparation of a sodium-dependent glucose transporter (SGLT) inhibitor.

Disclosed is a homogeneous polysaccharide, monosaccharide components of the homogeneous polysaccharide including mannose and glucose; wherein the main chain structure of the homogeneous polysaccharide is an alpha-(1→4)-linked glucose pyranose main chain; wherein the average molecular weight of the homogeneous polysaccharide is 11.1 ± 5.0 kDa. The homogeneous polysaccharide of the present application can be used for preventing and treating chronic liver disease.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an inhalable powder preparation based on screened lactose and a preparation method of the inhalable powder preparation. The inhalable powder preparation is prepared from the following raw materials in parts by weight: 1 to 1.25 parts of active pharmaceutical ingredients, 55 to 60 parts of screened lactose, 5 to 12 parts of modified lactose fine powder, 1 to 4 parts of hydroxypropyl-beta-cyclodextrin and 1 to 3 parts of oleanolic acid beta-D-glucopyranosyl ester. The modified lactose fine powder is palmitoyl chloride grafted and modified lactose fine powder, and the modification treatment can weaken the formation ability of a hydration layer on the surface of lactose, reduce the surface polarity and generate steric hindrance, so that the self-agglomeration tendency among the lactose fine powder is remarkably reduced, and the binding characteristic of the lactose fine powder and medicine particles is improved; furthermore, the dispersing performance and the lung deposition efficiency of the preparation are remarkably improved. In addition, the hydroxypropyl-beta-cyclodextrin and the oleanolic acid beta-D-glucopyranosyl ester are matched for use, so that the stability of the preparation can be remarkably improved.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

The invention relates to a crystalline complex of 1-cyano-2-(4-cyclotetramethyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene and a natural amino acid, methods for its preparation, as well as its uses for the preparation of medicines.

This invention discloses a sulfated arabinoglycoside, its preparation method, and its applications, belonging to the field of biomedical technology. The technical solution includes a sulfated arabinoglycoside derived from *Streptococcus linearis* polysaccharide; a degree of polymerization of 2-5; arabinose as the main monosaccharide, and containing galactose; the molar percentage of arabinose is not less than 80%, and the molar percentage of galactose is not more than 20%; the main chain is composed of (1→4)-β-L-pyranose arabinose groups, with the sulfate groups of the arabinose mainly substituted at the C-3 position. This invention is applied to inhibiting the abnormal aggregation of human pancreatic islet amyloid peptide (hIAPP), solving the problem of the lack of safe and effective intervention methods for the abnormal aggregation of human pancreatic islet amyloid peptide in existing technologies. It features stable raw material sources, high safety, a simple and mild preparation method suitable for large-scale preparation, and the ability to inhibit the abnormal aggregation of human pancreatic islet amyloid peptide and reduce pancreatic β-cell damage.

The invention belongs to the technical field of antibacterial agent preparation, and provides an A-type mannosylerythritol lipid nano-emulsion as well as a preparation method and application thereof. The A-type mannosyrythritol lipid (MEL-A) is a biological surfactant with an amphiphilic characteristic, and comprises a hydrophilic group which takes 4-O-beta-D-mannopyranose-erythritol as a main component and a hydrophobic group which takes a fatty acid chain as a main component, and the A-type mannosyrythritol lipid (MEL-A) is a biological surfactant with an amphiphilic characteristic and comprises a hydrophilic group which takes 4-O-beta-D-mannopyranose-erythritol as a main component. The MEL-A has a broad-spectrum antibacterial characteristic on various microorganisms (including bacteria, fungi and yeasts). However, the water solubility is low. Tween 20 and glycerol monooleate are used as emulsifiers, and MEL-A is encapsulated in emulsion particles to form oil-in-water emulsion particles, so that the solubility of MEL-A is improved, the antibacterial performance of A-type mannosylerythritol lipid is not influenced, and the A-type mannosylerythritol lipid is expected to be used in the field of food safety protection.

The invention provides a method for improving the sugar-acid conversion rate in a shikimic acid fermentation production process. Comprising the following steps: S1, respectively preparing a seed culture medium and a fermentation culture medium, wherein the fermentation culture medium contains 0.1-0.4 g / L of methyl-alpha-D-glucopyranoside; s2, a seed culture stage: sequentially inoculating the escherichia coli bottle-combining seed solution into a primary seed tank and a secondary seed tank, and respectively culturing for a period of time; s3, fermentation culture stage: supplementing the culture solution after seed culture into a three-stage fermentation tank, and controlling the pH value of the fermentation solution to be 6.7-6.9 within 0-12 hours; the pH value of the fermentation liquor is 6.4-6.6 when the fermentation liquor is discharged from 12h to the tank, and co-culturing for 42-54h to obtain the fermentation liquor containing shikimic acid. Through double means of culture medium formula design, seed culture and fermentation culture process design, the conversion rate of synthesizing shikimic acid from glucose is synergistically increased, the overall operation is simple, the dosage of used methyl-alpha-D-glucopyranoside is small, the cost is low, more shikimic acid can be converted, and for medicine production enterprises, the method has a very good application prospect. The obvious cost-reducing and effect-increasing effects are realized.

The invention discloses an alcohol-salt system capable of efficiently dissolving carbohydrates. Alcohol with high-concentration salt is dissolved to form a molten salt alcohol adduct solvent system, and the solubility of carbohydrate in an alcohol solvent is improved by utilizing the complexing action between salt cations and hydroxyl of a pyranose ring. According to the invention, the problem of solubility of carbohydrates in alcohol solvents is solved, and a basis is provided for efficient conversion of carbohydrates in alcohol solvents.

The invention discloses saposhnicovia divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of natural polymers. The method has the advantages that the average relative molecular weight is measured through GPC, monosaccharide composition is analyzed through GC-MS, it is found that the average relative molecular weight of the saposhnicovia divaricata polysaccharide RSP-1 is 111125 Da, the protein content of the saposhnicovia divaricata polysaccharide RSP-1 is 1.29%, the saposhnicovia divaricata polysaccharide RSP-1 does not contain uronic acid and is neutral polysaccharide, and it is found that trace beta-pyranose exists. Meanwhile, the saposhnicovia divaricata polysaccharide RSP-1 disclosed by the invention can be used for remarkably relieving liver fat infiltration, reducing the number of ballooning and necrotic cells and relieving alcoholic liver injury.

The invention discloses a 4-sulfur-N-pyranoside compound as well as a preparation method and application thereof. The 4-sulfur-N-pyranoside compound shown in the formula (1) has TRIP13 inhibitory activity, can be used as a TRIP13 inhibitor, and can be used for preparing drugs for treating and / or preventing TRIP13 abnormity related diseases, such as multiple myeloma, lymphoma and the like. # imgabs0 #

This invention discloses a processing method for roasted sweet potatoes, belonging to the field of sweet potato processing technology. The method involves first placing the sweet potato at a suitable temperature for amylase activity, promoting the saccharification process and increasing its sweetness; simultaneously, allowing it to stand at a low temperature for an extended period allows the fructose inside to convert from furanose to pyranose, significantly increasing the sweetness; after roasting the sweet potato at high temperature, the surface is made sticky by lowering the temperature and increasing humidity, achieving a "sugar return" effect; finally, high-temperature treatment removes excess moisture, further enhancing the sweetness; and finally, vacuum packaging with nitrogen gas and low-temperature storage yields roasted sweet potatoes, effectively extending the shelf life of cooked sweet potatoes.

This invention relates to a method for producing an aqueous polymer dispersion by free radical-initiated aqueous emulsion polymerization of a monomer composition comprising 50% to 99.9% by weight of at least one (meth)acrylic acid C1 to C2. 10 Alkyl esters and / or vinyl aromatic compounds (Class I), or at least one vinyl aromatic compound and conjugated aliphatic diene by weight of 50% to 99.9% (Class II), or vinyl acetate, vinyl propionate, vinyl tert-carbonate, long-chain fatty acid vinyl esters and / or ethylene by weight of 50% to 99.9% (Class III), these amounts being based on total monomers in each case, the method being carried out by polymerizing the composition in the presence of an oligosaccharide having 1.5 to 10 β-1,4-glycosidic bonds linking pyranose units; relating to the dispersion obtained accordingly; and relating to the use of the dispersion as a binder, adhesive, sizing agent for fibers, for the production of coatings or for the production of paper coating formulations.

The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient:wherein R1 represents an aldopyranose residue, R2 represents a hydrogen atom or a hydroxy group, R3 represents —CH2—, —CH(OH)—CH2—, or —CH═CH—, R4 represents a hydrogen atom or CH3, x is 0 to 35, and y and z each represent an integer that satisfies y+z=0 to 3.

The invention relates to the technical field of feed additives, and provides an oligomeric atractylodes macrocephala polysaccharide BZ-3 as well as a preparation method and application thereof. The oligomeric atractylodes macrocephala polysaccharide BZ-3 is glucosan oligosaccharide composed of 14 monosaccharides, and specifically comprises the following components: 10 beta-furanfructose are connected through beta-1, 2 glucosidic bonds, then alpha-glucopyranose is connected through the beta-1, 2 glucosidic bonds, the tail end of the glucosan oligosaccharide is connected with 3 alpha-glucopyranose through alpha-1, 4 glucosidic bonds, and the molecular formula of the glucosan oligosaccharide is C72H144O72. According to the technical scheme, the problem that the application of the atractylodes macrocephala polysaccharide is limited due to the fact that the atractylodes macrocephala polysaccharide is insufficient in structural analysis and poor in quality controllability in the prior art is solved.

This invention discloses a reagent kit and method for the joint detection of glucose, cellobiose, and xylose in cellulose hydrolysate, belonging to the field of biomass conversion and analytical detection technology. The method includes the following steps: setting up three types of detection channels: a glucose oxidase detection channel that specifically responds to the glucose component; a β-glucosidase-glucose oxidase combined detection channel that responds to the total signal of glucose and cellobiose; and a pyranose oxidase detection channel that simultaneously responds to the combined signals of glucose, cellobiose, and xylose. Enzymatic colorimetric reactions are performed on the cellulose hydrolysate sample and the multi-component gradient standard solution in the three types of detection channels, respectively. A ternary linear calibration model is constructed based on the absorbance data of the three types of channels of the multi-component gradient standard solution. This method provides a rapid, low-cost, and highly specific detection method for glucose, cellobiose, and xylose in cellulose biomass hydrolysate, and has practical application value.

To provide an α-GalCer analogue that induces Th17-selective cytokine production.SOLUTION: The present invention provides a compound represented by the formula (I) in the figure (where A represents an α- or β-D-glycopyranosyl group, R1 represents an acyl group derived from a linear fatty acid monosubstituted with a hydroxy or nitro group, and R2 represents a linear aliphatic group which may be monosubstituted with a hydroxy group).SELECTED DRAWING: None

The invention discloses a metabolic antagonist solution which is obtained by dissolving a metabolic antagonist in water, the metabolic antagonist is L-2-enol hexolactone and / or 2-deoxy-D-glucose, and the invention also discloses an application of the metabolic antagonist solution in storage of crude rosin. The metabolism antagonist solution provided by the invention aims at glycolysis and energy metabolism of impurities such as pine needles and barks, and discoloration and degradation of the crude rosin in the storage process are blocked from the source; the L-2-enol hexanoic acid lactone oxidation product enters cells through glucose transporters such as GLUT1 / 3 / 4, competes for binding sites with glucose, and interferes with glycolysis and energy metabolism of impurities such as pine needles and barks; the 2-deoxy-D-glucose has a pyranoid ring conformation highly similar to that of glucose, is acidified into 2-deoxyglucose-6-phosphoric acid by hexokinase, and hijacks a glycolytic pathway, resulting in metabolic blocking and energy depletion.

The present invention relates to a compound of general formula (1), wherein the pyranose ring is α-D-galactopyranose, A is selected from, and the compound of structural formula (1) is suitable for use in a method for treating diseases associated with the binding of galectins (such as galectin-3) and mammalian (such as human) ligands. In addition, the present invention relates to a compound for treating diseases associated with the binding of galectins (such as galectin-3) and mammalian (such as human) ligands.

The present invention relates to a process for the synthesis of at least one C-glycoside comprising the following successive steps: (A) the introduction into a first mechanochemical reactor, separately or previously mixed, of at least one sugar in the form of pyranose and / or furanose and of the D and / or L series, said sugar having at least one hydroxyl function at the obligatorily free anomeric position, of a first reagent which is a β-diketone and of a base, in order to form a first initial mixture; (B1) at least a first grinding of said first initial mixture at a temperature greater than or equal to 20°C, in said first mechanochemical reactor, for a residence time less than or equal to 6 hours, so as to form a ketone C-glycoside; (C) the recovery at the outlet of the first mechanochemical reactor of a final mixture.The present invention also relates to the use of the mechanochemical reactor for synthesizing a C-glycoside or a C-glycoside derivative comprising said at least C-glycoside. Figure for the abstract: no figure.

The invention belongs to the technical field of biological medicine and food, and discloses a low-molecular-weight flammulina velutipes polysaccharide as well as a preparation method and application thereof. The flammulina velutipes polysaccharide with low molecular weight is prepared by preparing flammulina velutipes crude polysaccharide through an ultrasonic-assisted hot water extraction method and purifying through ion-exchange chromatography and gel chromatography. Through detection, the flammulina velutipes polysaccharide with low molecular weight is neutral polysaccharide, has alpha-type pyranoside, and is glucan which takes-> 4)-alpha-D-Glcp-(1-> and-> 4, 6)-alpha-D-Glcp-(1-> as main chains and alpha-D-Glcp-(1-> as side chains. Pharmacological experiments show that the flammulina velutipes polysaccharide with low molecular weight has a very strong anti-inflammatory effect on inflammation stimulated by lipopolysaccharide (LPS), and can play the anti-inflammatory effect by down-regulating the levels of dimethyl phosphatidyl ethanolamine and histamine.

This invention discloses the application of Jerusalem artichoke polysaccharide in the preparation of drugs for regulating intestinal flora, belonging to the field of intestinal flora drugs. The drugs for regulating intestinal flora use Jerusalem artichoke polysaccharide as the active ingredient. These drugs improve intestinal disorders by increasing the proliferation of beneficial intestinal bacteria and the content of short-chain fatty acids, metabolites of intestinal flora. The Jerusalem artichoke polysaccharide prepared by this invention contains uronic acid and pyranose, and is mainly composed of fructose and glucose, with an average molecular weight of 2228 Da. The preparation method of Jerusalem artichoke polysaccharide in this invention has high yield, low cost, and is suitable for industrial production.

The invention relates to the technical field of ionic liquid and biological medicine, in particular to multi-element biomass ionic liquid as well as a preparation method and a composition thereof. The name of the multi-element biomass ionic liquid is [N] XY, [N] represents a cation, X represents an anion cluster, and Y represents a hydrogen bond donor; the cation is derived from a compound containing a quaternary ammonium structure, the anion cluster is derived from amino acid and a derivative thereof, and the hydrogen bond donor is derived from pyranose and a derivative thereof or furanose and a derivative thereof. The compound can be used as a solvent and a stabilizer of indissolvable and unstable API (American Petroleum Institute), can completely replace a traditional volatile organic solvent, dissolves various indissolvable APIs, and reduces environmental and health damage caused by the traditional organic solvent.

The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a combination of kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose and E-6-O-p-coumaroylpaederoside methyl ester in tumor resistance or the preparation of an anti-tumor drug. The research of the present invention has shown that both a kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose compound monomer and an E-6-O-p-coumaroylpaederoside methyl ester compound monomer have very strong anti-tumor activity. In the in-vivo anti-tumor activity research, the inhibition rates thereof can reach 48.97% and 45.96%, respectively; and when both are combined to inhibit tumor cells, the research reveals that the two monomers have an obvious effect of synergistically inhibiting tumors.

The invention relates to a corrosion inhibition enhanced chip cleaning agent as well as a preparation method and application thereof, and the corrosion inhibition enhanced chip cleaning agent comprises the following components in parts by weight: 0.001-0.01 part of a pyranoside corrosion inhibitor; 0.1 to 0.5 part of a chelating agent; 0.1 to 2 parts of organic acid; 0.1 to 2 parts of fluoride; 60-90 parts of an organic solvent; and 20 to 50 parts of ultrapure water, wherein the pyranoside corrosion inhibitor is alkyl sulfo-pyranoside. The alkyl sulfo-pyranoside corrosion inhibitor is adopted, Al < + > sites in an aluminum surface solution can be combined with sulfur atoms to form coordinate bonds, and molecules are directionally adsorbed to the aluminum surface. Sulfur can form a coordination intermediate with metal ions in pollutants due to the strong coordination capacity, the binding energy of the sulfur and an aluminum matrix is reduced, so that the dissolution of the chelating agent to the pollutants is promoted, hydroxyl on a pyranose ring can form a hydrogen bond network with a hydroxylation layer on the aluminum surface, the adhesive force of molecules and an oxidation film is enhanced, and the corrosion inhibition effect is enhanced.

The invention belongs to the field of organic synthesis and carbohydrate chemistry, and particularly discloses a carbohydrate hydroxyl region selective sulfonylation method. According to the method, a reaction mechanism is switched by selectively adding or omitting a palladium catalyst: when the palladium catalyst, a ligand and silver salt coexist, the system selectively sulfonylates equatorial hydroxyl; when a palladium catalyst is not added and only the ligand and the silver salt are retained, the system is selectively sulfonylated into axial or paraaxial hydroxyl. The method is easy and convenient to operate, accurate regulation and control of regioselectivity can be achieved without replacing ligands or additives, and the method has high selectivity and excellent substrate universality and is suitable for various pyranoside substrates and sulfonylation reagents. The obtained sulfonylation product is a key intermediate for synthesizing carbohydrate drugs, natural products and biological probes, and has a wide application prospect.

The invention belongs to the crossing field of bioengineering and pharmaceutical technology, and particularly relates to a heterologous expression technology of 2-deoxyribose-5-phosphate aldolase derived from rhodococcus ruber SD3 and optimization of aldol condensation reaction conditions of substrates acetaldehyde and chloroacetaldehyde catalyzed by the aldolase. The enzyme can catalyze a substrate to specifically synthesize a statin drug key intermediate (3R, 5S)-6-chloro-2, 4, 6-trideoxy pyranoside, the conversion rate can reach 44.45%, and a new biological catalysis approach and technical support are provided for efficient and green production of statin drugs. The rhodococcus ruber SD3 is preserved in the China Center for Type Culture Collection, and the preservation number of the rhodococcus ruber SD3 is CCTCC NO: M 2012035.